Gene Flow and Individual Relatedness Suggest Population Spatial Connectivity of Sinogastromyzon sichangensis (Cypriniformes: Balitoridae) in the Chishui River, China

stjosephs-hospital

 

  • Sinogastromyzon sichangensisis a hillstream loach endemic to the upper Yangtze River, China. It is unclear whether this fish lives in a very restricted area or may be dispersed over a long distance. In the present study spatial connectivity of populations of  sichangensis was investigated based on 343 individuals collected from 12 sites of Chishui River and employing 22 microsatellite loci.
  • The results of genetic diversity analysis showed that observed heterozygosity (HO) and polymorphism information content (PIC) ranged from 0.5653 to 0.6999 and 0.8513 to 0.8819, respectively. Population structure analysis suggested that  sichangensishad an unclear genetic structure. AMOVA showed that 69.36% of genetic variation was attributed to differentiation within individuals and all the pairwise genetic differentiation indices (FST) were low (mean FST = 0.0344), indicating weak differentiation among these populations.
  • Estimation of gene flow showed frequent flow among populations, and contemporary levels (mean contemporary migration rate, mc= 0.0131) were approximately equal to historical levels (mean historical migration rate, mh = 0.0147).
  • Individual relatedness analysis revealed a high level of sibship within and among different populations. The frequent gene flow and widespread sibship were due to  sichangensislaying drifting eggs which travel for a long distance until hatching, after which the juveniles or adults migrate upstream. The results of unclear geographic structure and frequent exchange also indicate that it is necessary to decrease the negative impacts of anthropogenic activities on the connectivity of rivers to protect the migration routes of S. sichangensis.

 

Case Report: Identification of a Novel Variant (m.8909T>C) of Human Mitochondrial ATP6 Gene and Its Functional Consequences on Yeast ATP Synthase

 

With the advent of next generation sequencing, the list of mitochondrial DNA (mtDNA) mutations identified in patients rapidly and continuously expands. They are frequently found in a limited number of cases, sometimes a single individual (as with the case herein reported) and in heterogeneous genetic backgrounds (heteroplasmy), which makes it difficult to conclude about their pathogenicity and functional consequences.

As an organism amenable to mitochondrial DNA manipulation, able to survive by fermentation to loss-of-function mtDNA mutations, and where heteroplasmy is unstable, Saccharomyces cerevisiae is an excellent model for investigating novel human mtDNA variants, in isolation and in a controlled genetic context. We herein report the identification of a novel variant in mitochondrial ATP6 gene, m.8909T>C. It was found in combination with the well-known pathogenic m.3243A>G mutation in mt-tRNALeu.

We show that an equivalent of the m.8909T>C mutation compromises yeast adenosine tri-phosphate (ATP) synthase assembly/stability and reduces the rate of mitochondrial ATP synthesis by 20-30% compared to wild type yeast. Other previously reported ATP6 mutations with a well-established pathogenicity (like m.8993T>C and m.9176T>C) were shown to have similar effects on yeast ATP synthase. It can be inferred that alone the m.8909T>C variant has the potential to compromise human health.

Investigating the Role of Telomere and Telomerase Associated Genes and Proteins in Endometrial Cancer

 

  • Endometrial cancer (EC) is the commonest gynaecological malignancy. Current prognostic markers are inadequate to accurately predict patient survival, necessitating novel prognostic markers, to improve treatment strategies. Telomerase has a unique role within the endometrium, whilst aberrant telomerase activity is a hallmark of many cancers.
  • The aim of the current in silico study is to investigate the role of telomere and telomerase associated genes and proteins (TTAGPs) in EC to identify potential prognostic markers and therapeutic targets. Analysis of RNA-seq data from The Cancer Genome Atlas identified differentially expressed genes (DEGs) in EC (568 TTAGPs out of 3467) and ascertained DEGs associated with histological subtypes, higher grade endometrioid tumours and late stage EC.
  • Functional analysis demonstrated that DEGs were predominantly involved in cell cycle regulation, while the survival analysis identified 69 DEGs associated with prognosis. The protein-protein interaction network constructed facilitated the identification of hub genes, enriched transcription factor binding sites and drugs that may target the network.
  • Thus, our in silico methods distinguished many critical genes associated with telomere maintenance that were previously unknown to contribute to EC carcinogenesis and prognosis, including NOP56WFS1ANAPC4and TUBB4A. Probing the prognostic and therapeutic utility of these novel TTAGP markers will form an exciting basis for future research.
stjosephs-hospital

stjosephs-hospital

CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy

 

Cancer immunotherapy has been emerged as a promising strategy for treatment of a broad spectrum of malignancies ranging from hematological to solid tumors. One of the principal approaches of cancer immunotherapy is transfer of natural or engineered tumor-specific T-cells into patients,

a so called “adoptive cell transfer”, or ACT, process. Construction of allogeneic T-cells is dependent on the employment of a gene-editing tool to modify donor-extracted T-cells and prepare them to specifically act against tumor cells with enhanced function and durability and least side-effects. In this context, CRISPR technology can be used to produce universal T-cells, equipped with recombinant T cell receptor (TCR) or chimeric antigen receptor (CAR), through multiplex genome engineering using Cas nucleases.

The robust potential of CRISPR-Cas in preparing the building blocks of ACT immunotherapy has broaden the application of such therapies and some of them have gotten FDA approvals. Here, we have collected the last investigations in the field of immuno-oncology conducted in partnership with CRISPR technology. In addition, studies that have addressed the challenges in the path of CRISPR-mediated cancer immunotherapy, as well as pre-treatment applications of CRISPR-Cas have been mentioned in detail.

Deregulated microRNAs Are Associated with Patient Survival and Predicted to Target Genes That Modulate Lung Cancer Signaling Pathways

 

Background: Although the advances in diagnostic and treatment strategies, lung cancer remains the leading cause of cancer-related deaths, worldwide, with survival rates as low as 16% in developed countries. Low survival rates are mainly due to late diagnosis and the lack of effective treatment. Therefore, the identification of novel, clinically useful biomarkers is still needed for patients with advanced disease stage and poor survival.

Micro(mi)RNAs are non-coding RNAs and potent regulators of gene expression with a possible role as diagnostic, prognostic and predictive biomarkers in cancer.

Methods: We applied global miRNA expression profiling analysis using TaqMan® arrays in paired tumor and normal lung tissues (n = 38) from treatment-naïve patients with lung adenocarcinoma (AD; n = 23) and lung squamous cell carcinoma (SCC; n = 15). miRNA target genes were validated using The Cancer Genome Atlas (TCGA) lung AD (n = 561) and lung SCC (n = 523) RNA-Seq datasets.

Results: We identified 33 significantly deregulated miRNAs (fold change, FC ≥ 2.0 and p < 0.05) in tumors relative to normal lung tissues, regardless of tumor histology. Enrichment analysis confirmed that genes targeted by the 33 miRNAs are aberrantly expressed in lung AD and SCC, and modulate known pathways in lung cancer. Additionally, high expression of miR-25-3p was significantly associated (p < 0.05) with poor patient survival, when considering both tumor histologies.

Conclusions: miR-25-3p may be a potential prognostic biomarker in non-small cell lung cancer. Genes targeted by miRNAs regulate EGFR and TGFβ signaling, among other known pathways relevant to lung tumorigenesis.

 

Human V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

RD-FOS-Hu-48Tests 48 Tests
EUR 600

Human V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

RD-FOS-Hu-96Tests 96 Tests
EUR 830.4

Recombinant Human FOS-B

7-05212 2µg Ask for price

Recombinant Human FOS-B

7-05213 5µg Ask for price

Recombinant Human FOS-B

7-05214 10µg Ask for price

FOS B antibody

29246-100ul 100ul
EUR 302.4

anti-Fos B

YF-PA23732 50 ul
EUR 400.8
Description: Mouse polyclonal to Fos B

anti-Fos B

YF-PA11841 50 ul
EUR 435.6
Description: Mouse polyclonal to Fos B

anti-Fos B

YF-PA11842 50 ug
EUR 435.6
Description: Mouse polyclonal to Fos B

anti-Fos B

YF-PA11843 100 ul
EUR 483.6
Description: Rabbit polyclonal to Fos B

anti-Fos B

YF-PA11844 100 ug
EUR 483.6
Description: Rabbit polyclonal to Fos B

Mouse V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

DLR-FOS-Mu-48T 48T
EUR 609.6
Description: A sandwich quantitative ELISA assay kit for detection of Mouse V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) in samples from tissue homogenates or other biological fluids.

Mouse V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

DLR-FOS-Mu-96T 96T
EUR 793.2
Description: A sandwich quantitative ELISA assay kit for detection of Mouse V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) in samples from tissue homogenates or other biological fluids.

Rat V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

DLR-FOS-Ra-48T 48T
EUR 633.6
Description: A sandwich quantitative ELISA assay kit for detection of Rat V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) in samples from tissue homogenates, cell lysates or other biological fluids.

Rat V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

DLR-FOS-Ra-96T 96T
EUR 828
Description: A sandwich quantitative ELISA assay kit for detection of Rat V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) in samples from tissue homogenates, cell lysates or other biological fluids.

Mouse V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

RDR-FOS-Mu-48Tests 48 Tests
EUR 640.8

Mouse V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

RDR-FOS-Mu-96Tests 96 Tests
EUR 890.4

Rat V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

RDR-FOS-Ra-48Tests 48 Tests
EUR 669.6

Rat V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

RDR-FOS-Ra-96Tests 96 Tests
EUR 931.2

Mouse V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

RD-FOS-Mu-48Tests 48 Tests
EUR 613.2

Mouse V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

RD-FOS-Mu-96Tests 96 Tests
EUR 850.8

Rat V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

RD-FOS-Ra-48Tests 48 Tests
EUR 640.8

Rat V-Fos FBJ Murine Osteosarcoma Viral Oncogene Homolog (FOS) ELISA Kit

RD-FOS-Ra-96Tests 96 Tests
EUR 890.4

FOS-B Human Recombinant Protein

PROTP53539 Regular: 5ug
EUR 574.8
Description: FOS-B Human Recombinant (a.a. 113-151) expressed in E.coli, shows a 32 kDa SDS-PAGE (Including GST).;The FOS-B is purified by proprietary chromatographic techniques.

Fos B Polyclonal Antibody

ABP51360-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of Fos B from Human, Mouse, Monkey. This Fos B antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Fos B around the non-phosphorylation site of S27

Fos B Polyclonal Antibody

ABP51360-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of Fos B from Human, Mouse, Monkey. This Fos B antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Fos B around the non-phosphorylation site of S27

Fos B Polyclonal Antibody

ABP51360-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of Fos B from Human, Mouse, Monkey. This Fos B antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Fos B around the non-phosphorylation site of S27

FOS B Conjugated Antibody

C29246 100ul
EUR 476.4

Fos B Polyclonal Antibody

ES2359-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against Fos B from Human/Mouse/Monkey. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Fos B Polyclonal Antibody

ES2359-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against Fos B from Human/Mouse/Monkey. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Anti-Fos B antibody

STJ93103 200 µl
EUR 236.4
Description: Rabbit polyclonal to Fos B.

Recombinant (E.Coli, GST) Human FOS-B

RP-945 2 ug
EUR 416.4

Anti-Fos B/FOSB Antibody

PA1478 100ug/vial
EUR 352.8

Anti-Fos B/FOSB Antibody

RP1086 100ug/vial
EUR 400.8

Fos B (phospho Ser27) Polyclonal Antibody

ABP54356-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of Fos B phospho Ser27) from Human, Mouse. This Fos B phospho Ser27) antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Fos B around the phosphorylation site of S27

Fos B (phospho Ser27) Polyclonal Antibody

ABP54356-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of Fos B phospho Ser27) from Human, Mouse. This Fos B phospho Ser27) antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Fos B around the phosphorylation site of S27

Fos B (phospho Ser27) Polyclonal Antibody

ABP54356-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of Fos B phospho Ser27) from Human, Mouse. This Fos B phospho Ser27) antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Fos B around the phosphorylation site of S27

Anti-Fos B Rabbit Monoclonal Antibody

M01569 100ug/vial
EUR 476.4
Description: Rabbit Monoclonal Fos B Antibody. Validated in IP, IF, IHC, ICC, WB and tested in Human, Mouse, Rat.

Fos B (phospho Ser27) Polyclonal Antibody

ES5355-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against Fos B (phospho Ser27) from Human/Mouse. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Fos B (phospho Ser27) Polyclonal Antibody

ES5355-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against Fos B (phospho Ser27) from Human/Mouse. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Anti-Phospho-Fos B (S27) antibody

STJ91338 200 µl
EUR 236.4
Description: Rabbit polyclonal to Phospho-Fos B (S27).

Recombinant Human FOS-B Protein, Untagged, E.coli-10ug

QP11898-10ug 10ug
EUR 663.6

Recombinant Human FOS-B Protein, Untagged, E.coli-2ug

QP11898-2ug 2ug
EUR 294

Recombinant Human FOS-B Protein, Untagged, E.coli-5ug

QP11898-5ug 5ug
EUR 403.2

Fmoc-b,b-diphenyl-Ala-OH

B-2725.0250 250.0mg
EUR 166.8
Description: Sum Formula: C30H25NO4; CAS# [201484-50-6]

Fmoc-b,b-diphenyl-Ala-OH

B-2725.1000 1.0g
EUR 428.4
Description: Sum Formula: C30H25NO4; CAS# [201484-50-6]

Fmoc-b,b-diphenyl-Ala-OH

B-2725.5000 5.0g
EUR 1603.2
Description: Sum Formula: C30H25NO4; CAS# [201484-50-6]

Phenolics Mix B

8040-B 1ML
EUR 61.56

Analyte Mix B

507-B 1ML
EUR 182.4

Analyte Mix B

5081-B 1ML
EUR 129.96

c-Fos (c-FOS) Antibody

20-abx134133
  • EUR 427.20
  • EUR 644.40
  • EUR 260.40
  • 100 ul
  • 200 ul
  • 30 ul

c-Fos (c-FOS) Antibody

20-abx134134
  • EUR 427.20
  • EUR 644.40
  • EUR 260.40
  • 100 ul
  • 200 ul
  • 30 ul

c-Fos (c-Fos) Antibody

abx038361-100ug 100 ug
EUR 469.2

c-Fos (c-FOS) Antibody

20-abx009253
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

c-Fos (c-fos) Antibody

abx032883-400ul 400 ul
EUR 627.6

c-Fos (c-fos) Antibody

abx032883-80l 80 µl
EUR 343.2

c-Fos (c-FOS) Antibody

abx432497-200ul 200 ul
EUR 460.8

Human Proto-Oncogene C-Fos (FOS) ELISA Kit

20-abx151580
  • EUR 8534.40
  • EUR 4550.40
  • EUR 1054.80
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

Human Proto-Oncogene C-Fos (FOS) CLIA Kit

20-abx492601
  • EUR 9567.60
  • EUR 5095.20
  • EUR 1177.20
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

Human Proto-oncogene c-Fos (FOS) ELISA Kit

abx570165-96tests 96 tests
EUR 801.6

Human FOS(Proto-oncogene c-Fos) ELISA Kit

EH1465 96T
EUR 681.12
Description: Method of detection: Double Antibody, Sandwich ELISA;Reacts with: Homo sapiens;Sensitivity: 0.188 ng/ml

Human FOS/ Proto-oncogene c-Fos ELISA Kit

E0936Hu 1 Kit
EUR 685.2

Human Proto- oncogene c- Fos, FOS ELISA KIT

ELI-04266h 96 Tests
EUR 988.8

Fmoc-b-Ala-OPfp

B-1765.0005 5.0g
EUR 283.2
Description: Sum Formula: C24H16F5NO4; CAS# [149303-38-8]

Fmoc-b-Ala-OPfp

B-1765.0025 25.0g
EUR 1009.2
Description: Sum Formula: C24H16F5NO4; CAS# [149303-38-8]

Fmoc-b-Ala-OH

B-1025.0005 5.0g
EUR 138
Description: Sum Formula: C18H17NO4; CAS# [35737-10-1]

Fmoc-b-Ala-OH

B-1025.0025 25.0g
EUR 283.2
Description: Sum Formula: C18H17NO4; CAS# [35737-10-1]

Fmoc-b-Ala-OH

B-1025.0100 100.0g
EUR 762
Description: Sum Formula: C18H17NO4; CAS# [35737-10-1]

Purgeable Gases Mix B

624-B 1ML
EUR 249.66

Purgeable Gases Mix B

5022-B 1ML
EUR 27.36

Proto-Oncogene C-Fos (FOS) Antibody

20-abx159505
  • EUR 326.40
  • EUR 276.00
  • 100 ug
  • 50 ug

Proto-Oncogene C-Fos (FOS) Antibody

abx159506-100ul 100 ul
EUR 560.4

Proto-Oncogene C-Fos (FOS) Antibody

20-abx000621
  • EUR 493.20
  • EUR 710.40
  • EUR 218.40
  • EUR 376.80
  • 100 ul
  • 200 ul
  • 20 ul
  • 50 ul

Proto-Oncogene C-Fos (FOS) Antibody

abx116993-100ug 100 ug
EUR 560.4

Proto-Oncogene C-Fos (FOS) Antibody

abx010792-100ug 100 ug
EUR 510

Proto-Oncogene C-Fos (FOS) Antibody

abx011653-100ul 100 ul
EUR 493.2

Proto-Oncogene C-Fos (FOS) Antibody

20-abx012949
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Proto-Oncogene C-Fos (FOS) Antibody

20-abx013037
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Proto-Oncogene C-Fos (FOS) Antibody

abx332426-100ul 100 ul
EUR 510

Proto-Oncogene C-Fos (FOS) Antibody

abx332167-100ul 100 ul
EUR 510

Proto-Oncogene C-Fos (FOS) Antibody

abx332234-100ul 100 ul
EUR 510

Proto-Oncogene C-Fos (FOS) Antibody

20-abx242109
  • EUR 493.20
  • EUR 360.00
  • 100 ul
  • 50 ul

Proto-Oncogene C-Fos (FOS) Antibody

20-abx326934
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Proto-Oncogene C-Fos (FOS) Antibody

20-abx328416
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Proto-Oncogene C-Fos (FOS) Antibody

20-abx328953
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Proto-Oncogene C-Fos (FOS) Antibody

20-abx327051
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

FOS antibody

70R-34384 100 ug
EUR 392.4
Description: Rabbit polyclonal FOS antibody

FOS antibody

70R-34398 100 ug
EUR 392.4
Description: Rabbit polyclonal FOS antibody

Fos antibody

70R-34513 100 ug
EUR 392.4
Description: Rabbit polyclonal Fos antibody

Fos antibody

70R-31126 100 ug
EUR 392.4
Description: Rabbit polyclonal Fos antibody

Related Post

stjosephs-hospital

A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaA Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Background: Induction chemotherapy (IC) adopted by concurrent chemoradiotherapy is the mainstay remedy for sufferers with locoregionally superior nasopharyngeal carcinoma. Nevertheless, some sufferers acquire little profit and expertise pointless poisonousities from IC.